Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
Contents

1. About Us
2. Our Portfolio
3. Our Team
4. Our Strategy
CASI is a U.S. biopharmaceutical company with an aggressive vision to bring innovative pharmaceutical products to China, the U.S., and throughout the world.

Our first strategic focus is hematology-oncology and over time will expand into other attractive therapeutic markets.
Key Milestones

✓ **EVOMELA®** (Melphalan Hydrochloride for Injection): China marketing approval November 2018 under new priority review guidelines
  • Indication: treatment of Multiple Myeloma

✓ Established top-tier 50 person *marketing/sales team dedicated for EVOMELA®*

✓ **ZEVALIN®**: NMPA CTA approval to conduct confirmatory trial received February 2019
  • Indication: treatment of Non-Hodgkin’s Lymphoma

✓ **MARQIBO®**: NMPA CTA approval to conduct confirmatory trial received March 2019
  • Indication: treatment of Acute Lymphoblastic Leukemia

✓ **Anti-CD38 mAb (CID-103)**: In-License exclusive worldwide rights to novel anti-CD38 from Black Belt Therapeutics April 2019
  • Global IND/Phase 1 ready; Indications include Multiple Myeloma and other CD38+ malignancies

✓ **State-of-the-art GMP manufacturing facility construction**, strategically located in Wuxi, China
CASI Pharmaceuticals (NASDAQ: CASI)
US and China Synergy

- U.S. NASDAQ-listed biopharmaceutical company with seamless cross-border operations in Rockville, Maryland and Beijing, China
  - 90+ employees in U.S. & China; global operations led by senior executive team in the U.S.
- Management team with extensive hematology-oncology expertise and networks in U.S./China; maximizing development and commercialization synergies
- First hematology drug launch in China fiscal 2019
  - Melphalan Hydrochloride, marketed in the U.S. as EVOMELA® for multiple myeloma, transitioning CASI into a commercial enterprise
- Diverse pipeline of in-licensed drugs for hematology-oncology and a portfolio of U.S. ANDAs for multiple indications globally
- Providing patients and partners with a full range of solutions to effectively combat diseases and improve quality of life
- State-of-the-art GMP manufacturing facility scheduled for construction in 2019 in Wuxi, China
- Focused on acquiring & licensing late-stage or approved products
Build a dynamic, fully integrated biopharmaceutical company with an innovative portfolio to address patients’ unmet medical needs in China, the U.S. and globally through licensing and acquisitions
CASI is building an innovative product portfolio initially focusing on hematology and oncology
Diversified Portfolio of Approved and Pipeline Products

**Greater China Rights**

*Licensed From SPPI*

- **Evomela (melphalan) for Injection**
  - China NMPA market approval November 2018 with commercial launch in 2019
  - China NMPA CTA registration trial approval February 2019

- **ZEVALIN (ibritumomab tiuxetan)**
  - China NMPA CTA registration trial approval March 2019

**Global Rights**

*Licensed From Black Belt: CID-103*

- Anti-CD38 Monoclonal Antibody
  - Potential best-in-class
  - Global IND/IMPD stage of development
  - Phase 1 trials to start in late 2019/early 2020
  - Potential to be 1st China domestically manufactured anti-CD38

**U.S. FDA ANDAs**

*Acquired From Sandoz:*

- 19 FDA Approved ANDAs
- 4 FDA Pending ANDAs

*Acquired TDF from Laurus Labs:*

- ANDA for tenofovir disoproxil fumarate (TDF)

**Diverse Portfolio Across Attractive Therapeutic Area**

- Hypertension/PVD
- Metabolic Disorders
- CNS
- Anti-inflammatory/pain
- Others
EVOMELA® Approved in China for Multiple Myeloma

- Evomela® is the **only** approved melphalan product for China market
- In China, high awareness and anticipation of Evomela® as an **innovative, branded new treatment for multiple myeloma**
- Evomela® is **stable and easy** to handle for physicians
- Evomela® provides **best choice** of preparative regimen
CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that recognizes a unique epitope on CD38. It was engineered to have strong ADCC activity against CD38 malignant cells and to reduce certain safety issues observed with existing treatments.

Encouraging preclinical efficacy & safety profile compared to other CD38 mAbs:

- Demonstrates greater ADCC activity over Daratumumab and other anti-CD38 mAbs
- In vivo activity outperforms Daratumumab and other anti-CD38 mAbs
  — Demonstrates Significant Survival Improvement in Daudi, Ramos and Raji Xenograft models
CID-103, a Potential Best-in-Class anti-CD38

- CASI has global responsibility for development and commercialization activities
- CID-103 is currently at global IND/IMPD submission stage of development
- Successful pre CTA Scientific Advice discussions with EU and US regulatory agencies in 2017
- Phase 1 trials expected to start late 2019 or early 2020
- Potential to be the first China domestically manufactured anti-CD38 for China market
GMP Manufacturing Facility in Wuxi, China

- Building state-of-the-art GMP manufacturing facility strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China
  —Currently in design phase, breaking ground on Phase 1 in 2019
- Backing from Wuxi government
- Centrally located with convenience of mass transportation (direct train from the airport)
- Can accommodate oral solids, parenterals, biologics/cellular manufacturing with commercial scale production
- In-house manufacturing facility will allow greater controls over quality and cost of goods
Our Team

Management team and Board of Directors with decades of combined experience in drug development/commercialization and creating innovative companies
Management Team

Wei-Wu He, Ph.D.
Chairman and Chief Executive Officer
• In 2000, Dr. He established Emerging Technology Partners (ETP), a biomedical focused venture fund
• Chairman of the Board, Origene

Alexander A. Zukiwski, M.D.
Chief Medical Officer
• 21 years of global drug development experience
• Former CEO & CMO of Arno Therapeutics
• CMO & Executive VP of Clinical Research at MedImmune
• Former Clinical Development Heat at J&J

James E. Goldschmidt, Ph.D.
Senior Vice President, Business Development
• Over 25 years of commercial & business development experience
• Big Pharma: J&J, Wyeth-Pfizer, GSK
• Start-ups: Macrophage Therapeutics, ImmuneXcite, TetraLogic Pharmaceuticals

Larry Zhang
President, CASI China
• Former VP, Novartis, China
• Former, CEO, Sandoz China
• Held leadership roles at Bayer Asia Pacific Region & Greater China region

George Chi, CPA, CFA
Chief Financial Officer
• Former Vice President, Finance at Flavor Holdings
• Former Finance Director at Unilever

Cynthia W. Hu
COO, General Counsel & Secretary
• Former senior attorney at international law firms with focus on public companies, financings, securities, governance and M&A
• Former corporate & securities associate general counsel at a Fortune 50 NYSE-listed financial institution

Larry Zhang
President, CASI China
• Former VP, Novartis, China
• Former, CEO, Sandoz China
• Held leadership roles at Bayer Asia Pacific Region & Greater China region

George Chi, CPA, CFA
Chief Financial Officer
• Former Vice President, Finance at Flavor Holdings
• Former Finance Director at Unilever

Cynthia W. Hu
COO, General Counsel & Secretary
• Former senior attorney at international law firms with focus on public companies, financings, securities, governance and M&A
• Former corporate & securities associate general counsel at a Fortune 50 NYSE-listed financial institution
Board of Directors

WEI-WU HE, PH.D.
Chairman & CEO
CEO, CASI Pharmaceuticals; IDG-ACCEL China Fund Venture Partner; Managing Director ETP Global Fund, L.P.; Chairman, OriGene Technologies, Inc.

QUAN ZHOU, PH.D.
Compensation Committee
Founder, Managing Director & General Partner at IDG Capital Partners

JAMES HUANG
Audit Committee
General Partner, Kleiner Perkins Caufield & Byers China, Launched Panacea Venture in 2017

RAJESH SHROTRIYA, M.D.
Former Chairman & CEO of Spectrum Pharmaceuticals, Inc., 2000-2017

ALEXANDER WU, PH.D.
Audit & Compensation Committees
Former CEO, Crown Biosciences, Inc., 2006-2017

FRANKLIN SALISBURY, JR.
Audit & Compensation Committees
Co-founder & Director of AIM-HI Translational Research (a subsidiary of NFCR); Former CEO of NFCR

KEN K. REN, PH.D.
Former President of Accelovance (China) (now Linical Accelovance); founder of ImmunoVentis, Inc.; former Chief Investment Director of CCBI Healthcare Fund of China Construction Bank
CASi is entering a commercial phase in China and continues to build momentum for a promising future by expanding our product portfolio.

Through our partnering efforts, we build mutually beneficial relationships in order to provide patients in China and globally a range of solutions to treat diseases.
Business Strategy

- Significantly Enrich Pipeline Through Business Development
- Accelerate Registration & Commercialization
- Build State-of-the-Art GMP Facility
- Specialized Commercial Teams for Health Segments
- Produce Complex Generics for Niche Markets
CASI’s Value Proposition

A strategic partner for developing and commercializing innovative products in China, the U.S. and globally

- Leverage CASI Pharmaceutical’s expertise and resources to accelerate development and commercialization of innovative products into the China and U.S./global markets
- Reach value inflection points quickly to support global development programs
- Dedicated commercial team of experienced pharmaceutical professionals
- Bringing innovative medicines to 1.4 billion people in Greater China while addressing the U.S. and global markets efficiently
Recap

• U.S. based company – (NASDAQ: CASI)
• Launching first product in China fiscal 2019
• Strong cash runway, with expected revenue in 2019
• Backed by returning committed investors and new investors
• Experienced cross-border management team with deep knowledge of drug development, tech transfer & commercialization in both the Chinese & U.S. markets
• Initial products address and estimated $3 billion market opportunity in China & $700 million in U.S.
• Expected to rapidly penetrate Chinese market as centralized structure of patient care results in less fragmented delivery system
• Active BD to take advantage of scalable platform